The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

Date
2022
Author
Korkmaz, Serdal
Eser, Bulent
Altuntas, Fevzi
Tiryaki, Tarik Onur
Ulas, Turgay
ÖZATLI, DÜZGÜN
Akpinar, Seval
Dogu, Mehmet Hilmi
ÇELİK, SERHAT
Ekinci, Omer
Hindilerden, Ipek Yonal
Dal, Mehmet Sinan
Davulcu, Eren Arslan
Tekinalp, Atakan
Hindilerden, Fehmi
Ozcan, Busra Gokce
HACIBEKİROĞLU, TUBA
ERKURT, MEHMET ALİ
Bagci, Metin
Namdaroglu, Sinem
Korkmaz, Gulten
Bilgir, Oktay
ÇAĞLIYAN, GÜLSÜM AKGÜN
Ozturk, Hacer Berna Afacan
Serin, Istemi
TURGUT, BURHAN
Metadata
Show full item record
Abstract
We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least PR; 16 (8.7%) patients discontinued ibrutinib due to adverse events. The results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.
URI
http://hdl.handle.net/20.500.12627/185157
https://doi.org/10.1016/j.clml.2021.09.010
Collections